BCL2 and B-cell chronic lymphocytic leukemia: Despite significant advances in targeted therapies, including B‐cell receptor (BCR) signaling inhibitors and BCL–2 antagonists, CLL remains incurable for most patients, highlighting the need for novel therapeutic strategies.2, 3, 4